3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
5
Terminated
4
Suspended
2
Completed
2
Withdrawn
1
Not yet recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gastrointestinal
1
Dermatologic
1
Conditions
Melanoma
5
Carcinoma, Renal Cell
4
Squamous Cell Carcinoma of Head and Neck
3
Neoplasms
2
Lung Neoplasms
2
Urogenital Neoplasms
1
Solid Tumor, Adult
1
Recurrence
1
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
1
Mesothelioma, Malignant
1
Meningeal Neoplasms
1
Lymphoma, B-Cell
1
Lymphoma
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
Kidney Neoplasms
1
Head and Neck Neoplasms
1
Fallopian Tube Neoplasms
1
Disease Progression
1
Colorectal Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Squamous Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Bevacizumab
30
pembrolizumab
29
Oxaliplatin
28
Leucovorin
25
Fluorouracil
24
Irinotecan
22
Cetuximab
22
Capecitabine
19
Nivolumab
15
Specimen Handling
12
atezolizumab
11
Panitumumab
11
Colonoscopy
9
Carboplatin
9
regorafenib
8
Biopsy
8
trifluridine tipiracil drug combination
7
Trifluridine
7
Paclitaxel
7
Aspirin
7
balstilimab
6
Standard of Care
6
Cisplatin
6
tislelizumab
5
encorafenib
5
Radiotherapy
5
Magnetic Resonance Spectroscopy
5
Immunoglobulin G
5
Folfox protocol
5
Disulfides
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Colorectal Neoplasms
×
Interleukin-2
×
Clear all
NCT05902520
2026-01-08
ACT
AgonOx, Inc.
Phase 1
Active not recruiting
18 enrolled